StoxPiramal Pharma vs Rubicon Research: share price & financials comparison
NSE: PPLPHARMA vs RUBICON · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Piramal Pharma vs Rubicon Research at a glance
Piramal Pharma (PPLPHARMA) has a market capitalisation of ₹32,484 Cr, against ₹27,763 Cr for Rubicon Research (RUBICON). Over the past year Rubicon Research has returned +157.0%, compared with +22.0% for Piramal Pharma. Rubicon Research earns a higher return on equity (22.9% vs -2.6%). Piramal Pharma comes out ahead on valuation, momentum and technicals. Rubicon Research comes out ahead on size, profitability, growth and financial health. Across the scored metrics below, Piramal Pharma leads on 5 and Rubicon Research on 7. On StoxGud's 10-point checklist, Piramal Pharma scores 6/10 and Rubicon Research scores 8/10.
| Metric | Piramal Pharma | Rubicon Research |
|---|---|---|
| Size | ||
| Market cap | ₹32,484 Cr | ₹27,763 Cr |
| Revenue (latest FY) | ₹8,869 Cr | ₹1,754 Cr |
| Net profit (latest FY) | ₹-326 Cr | ₹247 Cr |
| Valuation | ||
| P/E | — | 85.5 |
| P/B | 3.99 | 19.60 |
| Dividend yield | 0.06% | 0.00% |
| Profitability | ||
| Return on equity | -2.6% | 22.9% |
| Net profit margin | -2.1% | 15.5% |
| Operating margin | 12.3% | 23.8% |
| Growth | ||
| Revenue growth (YoY) | +28.1% | +39.9% |
| Net profit growth (YoY) | — | +68.0% |
| Revenue CAGR (multi-year) | +7.8% | — |
| Financial health | ||
| Debt to equity | 0.70 | 0.28 |
| Momentum | ||
| 1-month return | +24.8% | +10.1% |
| 1-year return | +22.0% | +157.0% |
| 3-year CAGR | +26.7% | — |
| Distance from 52W high | -0.7% | -9.9% |
| Technicals | ||
| RSI (14) | 86 | 71 |
| Price vs 200-day avg | +35.6% | +34.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Piramal Pharma | Rubicon Research |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Piramal Pharma or Rubicon Research?
Piramal Pharma has a market cap of ₹32,484 Cr and Rubicon Research has a market cap of ₹27,763 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Piramal Pharma or Rubicon Research?
Rubicon Research did better: Piramal Pharma returned +22.0% and Rubicon Research returned +157.0% over one year.
What is the difference between Piramal Pharma and Rubicon Research?
Both are NSE-listed companies in Healthcare. Piramal Pharma is about 1.2 times the size of Rubicon Research by market cap. In the latest financial year Piramal Pharma reported revenue of ₹8,869 Cr and Rubicon Research ₹1,754 Cr. Operating margin is 12.3% for Piramal Pharma and 23.8% for Rubicon Research. Debt to equity is 0.70 for Piramal Pharma and 0.28 for Rubicon Research.
Which is better, Piramal Pharma or Rubicon Research?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Piramal Pharma leads on 5 and Rubicon Research on 7. Piramal Pharma is ahead on valuation, momentum and technicals. Rubicon Research is ahead on size, profitability, growth and financial health. On StoxGud's rules-based checklist Piramal Pharma scores 6/10 and Rubicon Research scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.